Karyopharm Therapeutics (KPTI) to Release Quarterly Earnings on Thursday

Karyopharm Therapeutics (NASDAQ:KPTI) will likely be issuing its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect Karyopharm Therapeutics to post earnings of ($2.26) per share and revenue of $33.16 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:00 AM ET.

Karyopharm Therapeutics Stock Up 2.8%

Shares of Karyopharm Therapeutics stock traded up $0.17 on Friday, hitting $6.26. 520,560 shares of the company were exchanged, compared to its average volume of 406,867. The company has a 50-day moving average price of $6.79 and a 200 day moving average price of $6.12. The stock has a market capitalization of $114.62 million, a price-to-earnings ratio of -0.43 and a beta of 0.21. Karyopharm Therapeutics has a 1-year low of $3.51 and a 1-year high of $10.38.

Institutional Trading of Karyopharm Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of KPTI. Baird Financial Group Inc. acquired a new stake in shares of Karyopharm Therapeutics during the second quarter worth about $45,000. XTX Topco Ltd purchased a new stake in Karyopharm Therapeutics during the 2nd quarter worth approximately $56,000. ADAR1 Capital Management LLC acquired a new stake in Karyopharm Therapeutics during the 3rd quarter worth approximately $164,000. Bank of America Corp DE boosted its position in Karyopharm Therapeutics by 26.8% in the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock valued at $726,000 after buying an additional 35,626 shares during the period. Finally, Bridgeway Capital Management LLC acquired a new position in shares of Karyopharm Therapeutics in the second quarter worth $163,000. 66.44% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

KPTI has been the subject of several analyst reports. The Goldman Sachs Group set a $12.00 target price on Karyopharm Therapeutics in a report on Wednesday, December 17th. Piper Sandler reaffirmed an “overweight” rating and set a $12.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, December 17th. Wall Street Zen upgraded shares of Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, November 8th. Royal Bank Of Canada reduced their price target on shares of Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research note on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.83.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.